
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/791429/publications.pdf Version: 2024-02-01



NODREDT MÃ1/11ED

#	Article	IF	CITATIONS
1	Lack of Association of Group A Streptococcal Infections and Onset of Tics. Neurology, 2022, 98, .	1.5	16
2	Interhelical interactions within the STIM1 CC1 domain modulate CRAC channel activation. Nature Chemical Biology, 2021, 17, 196-204.	3.9	22
3	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. Neurology, 2021, 96, e1680-e1693.	1.5	30
4	Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110226.	2.5	12
5	A role for pathogen risk factors and autoimmunity in encephalitis lethargica?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110276.	2.5	2
6	Resonance assignment of coiled-coil 3 (CC3) domain of human STIM1. Biomolecular NMR Assignments, 2021, 15, 433-439.	0.4	0
7	Brain Versus Blood: A Systematic Review on the Concordance Between Peripheral and Central Kynurenine Pathway Measures in Psychiatric Disorders. Frontiers in Immunology, 2021, 12, 716980.	2.2	32
8	Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline—Results From a Randomized Controlled Clinical Trial. Frontiers in Psychiatry, 2021, 12, 615261.	1.3	10
9	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110391.	2.5	43
10	Mycoplasma pneumoniae IgG positivity is associated with tic severity in chronic tic disorders. Brain, Behavior, and Immunity, 2021, 99, 281-288.	2.0	6
11	Childhood trauma, suicide risk and inflammatory phenotypes of depression: insights from monocyte gene expression. Translational Psychiatry, 2020, 10, 296.	2.4	37
12	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	2.8	36
13	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Frontiers in Psychiatry, 2019, 10, 458.	1.3	111
14	COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 375.	1.3	81
15	Childhood Adversity and Current Stress are related to Pro- and Anti-inflammatory Cytokines in Major Depression. Journal of Affective Disorders, 2019, 253, 270-276.	2.0	53
16	The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of Psychiatric Disorders. Frontiers in Pharmacology, 2019, 10, 1251.	1.6	103
17	Structural characterization of aerogels derived from enzymatically oxidized galactomannans of fenugreek, sesbania and guar gums. Carbohydrate Polymers, 2019, 207, 510-520.	5.1	22
18	A dual mechanism promotes switching of the Stormorken STIM1 R304W mutant into the activated state. Nature Communications, 2018, 9, 825.	5.8	45

#	Article	IF	CITATIONS
19	The effect of oxytocin on group formation and strategic thinking in men. Hormones and Behavior, 2018, 100, 100-106.	1.0	5
20	Rapid NMR-scale purification of 15N,13C isotope-labeled recombinant human STIM1 coiled coil fragments. Protein Expression and Purification, 2018, 146, 45-50.	0.6	10
21	Nonlinear detection of secondary isotopic chemical shifts in NMR through spin noise. Nature Communications, 2017, 8, 13914.	5.8	10
22	Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Journal of Psychiatric Research, 2017, 92, 139-146.	1.5	65
23	Detailed Evidence for an Unparalleled Interaction Mode between Calmodulin and Orai Proteins. Angewandte Chemie - International Edition, 2017, 56, 15755-15759.	7.2	12
24	(<i>Z</i>), Not (<i>E</i>) – An End to a Century of Confusion about the Doubleâ€Bond Stereoisomers of 3â€Aminoâ€2 yanoacrylates. European Journal of Organic Chemistry, 2017, 2017, 6408-6412.	1.2	4
25	Silver-, calcium-, and copper molybdate compounds: Preparation, antibacterial activity, and mechanisms. Biointerphases, 2017, 12, 05G607.	0.6	26
26	Oxytocin promotes altruistic punishment. Social Cognitive and Affective Neuroscience, 2017, 12, 1740-1747.	1.5	14
27	High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. Frontiers in Psychiatry, 2017, 8, 16.	1.3	33
28	Neuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation. Modern Problems of Pharmacopsychiatry, 2017, 31, 1-9.	2.5	18
29	Growth inhibition of <i>Escherichia coli</i> by zinc molybdate with different crystalline structures. Physica Status Solidi (A) Applications and Materials Science, 2016, 213, 1471-1478.	0.8	21
30	Use of Nuclear Spin Noise Spectroscopy to Monitor Slow Magnetization Buildup at Millikelvin Temperatures. ChemPhysChem, 2016, 17, 3035-3039.	1.0	6
31	Oxytocin course over pregnancy and postpartum period and the association with postpartum depressive symptoms. Archives of Women's Mental Health, 2016, 19, 571-579.	1.2	54
32	Obsessive-compulsive disorder – A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. Journal of Psychiatric Research, 2015, 68, 354-362.	1.5	22
33	The Role of Inflammation in Alzheimer's Disease. Current Topics in Neurotoxicity, 2015, , 313-336.	0.4	2
34	Resonance assignment of PsbP: an extrinsic protein from photosystem II of Spinacia oleracea. Biomolecular NMR Assignments, 2015, 9, 341-346.	0.4	3
35	Spin Noise Detection of Nuclear Hyperpolarization at 1.2â€K. ChemPhysChem, 2015, 16, 3859-3864.	1.0	8
36	Solution NMR and molecular dynamics reveal a persistent alpha helix within the dynamic region of PsbQ from photosystem II of higher plants. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1677-1686.	1.5	4

#	Article	IF	CITATIONS
37	Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatrica, 2014, 26, 347-355.	1.0	72
38	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 190-195.	2.5	10
39	Immunology of Schizophrenia. NeuroImmunoModulation, 2014, 21, 109-116.	0.9	68
40	Empathy in high-tech and high-touch medicine. Patient Education and Counseling, 2014, 95, 259-264.	1.0	17
41	Immunology of Major Depression. NeuroImmunoModulation, 2014, 21, 123-130.	0.9	136
42	Facility based cross-sectional study of self stigma among people with mental illness: towards patient empowerment approach. International Journal of Mental Health Systems, 2013, 7, 21.	1.1	42
43	Anti-inflammatory treatment in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 146-153.	2.5	77
44	Emotional and Cognitive Empathy in First-Year Medical Students. , 2013, 2013, 1-6.		20
45	The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina, 2013, 25, 292-8.	0.2	52
46	Infectious agents are associated with psychiatric diseases. Mental Illness, 2012, 4, 38-42.	0.8	9
47	Inflammation in Schizophrenia. Advances in Protein Chemistry and Structural Biology, 2012, 88, 49-68.	1.0	76
48	Impaired monocyte activation in schizophrenia. Psychiatry Research, 2012, 198, 341-346.	1.7	72
49	Immunological Treatment Options for Schizophrenia. Current Pharmaceutical Biotechnology, 2012, 13, 1606-1613.	0.9	26
50	Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now?. Journal of Psychopharmacology, 2011, 25, 713-714.	2.0	23
51	Attentional modulation of external speech attribution in patients with hallucinations and delusions. Neuropsychologia, 2011, 49, 805-812.	0.7	22
52	Inflammatory Biomarkers and Depression. Neurotoxicity Research, 2011, 19, 308-318.	1.3	106
53	Inside Cover: Tight Binding of Transition-State Analogues to a Peptidyl-Aminoacyl-L/D-Isomerase from Frog Skin (ChemBioChem 13/2011). ChemBioChem, 2011, 12, 1942-1942.	1.3	0
54	Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects. Current Pharmaceutical Design, 2011, 17, 130-136.	0.9	80

#	Article	IF	CITATIONS
55	Neuroinflammation, Microglia and Implications for Anti-Inflammatory Treatment in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-9.	1.1	93
56	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research, 2010, 121, 118-124.	1.1	227
57	COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Current Opinion in Investigational Drugs, 2010, 11, 31-42.	2.3	67
58	The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues in Clinical Neuroscience, 2009, 11, 319-332.	1.8	64
59	A psychoneuroimmunological perspective to Emil Kraepelins dichotomy. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 97-106.	1.8	111
60	Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Review of Neurotherapeutics, 2008, 8, 527-536.	1.4	184
61	Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opinion on Therapeutic Targets, 2008, 12, 1497-1507.	1.5	34
62	COX-2 Inhibition in Schizophrenia and Major Depression. Current Pharmaceutical Design, 2008, 14, 1452-1465.	0.9	94
63	Coherence pathway selection by cogwheel phase cycling in liquid-state NMR. Concepts in Magnetic Resonance Part A: Bridging Education and Research, 2007, 30A, 81-99.	0.2	10
64	Significant alterations in peripheral blood lymphocyte subsets in patients with somatoform disorder. Acta Neuropsychiatrica, 2007, 19, 368-375.	1.0	2
65	Pragmatic Studies on Protein-Resistant Self-Assembled Monolayers. Monatshefte Für Chemie, 2007, 138, 245-252.	0.9	7
66	Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches Dialogues in Clinical Neuroscience, 2007, 9, 161-171.	1.8	28
67	Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders. Expert Review of Neurotherapeutics, 2006, 6, 1017-1038.	1.4	59
68	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research, 2006, 10, 131-148.	1.3	205
69	Nuclear spin noise imaging. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6790-6792.	3.3	62
70	Clinical effects of COX?2 inhibitors on cognition in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 149-151.	1.8	118
71	Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome. Inflammopharmacology, 2004, 12, 271-275.	1.9	12
72	COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 14-22.	1.8	126

#	Article	IF	CITATIONS
73	A Novel Route to trans -Epoxidation of Terpinen-4-ol. Monatshefte Für Chemie, 2004, 135, 35-40.	0.9	4

Base-Catalysed Hydrolysis and Reactivity-Spectra Correlations of (Z)-4-Benzylidene-2-(Substituted) Tj ETQq0 0 0 rg $\frac{BT}{0.6}$ (Overlock 10 Tf 50)

75	Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia. American Journal of Psychiatry, 2002, 159, 1029-1034.	4.0	366
76	Comorbidity of Tourette's syndrome and schizophrenia—biological and physiological parallels. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1245-1252.	2.5	22
77	Increased anti-streptococcal antibodies in patients with Tourette's syndrome. Psychiatry Research, 2000, 94, 43-49.	1.7	69
78	Cellular and Humoral Immune System in Schizophrenia: A Conceptual Re-Evaluation. World Journal of Biological Psychiatry, 2000, 1, 173-179.	1.3	79
79	The Immune System and Schizophrenia: An Integrative View. Annals of the New York Academy of Sciences, 2000, 917, 456-467.	1.8	161
80	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neuroscience Letters, 1999, 259, 145-148.	1.0	56
81	Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 308-313.	1.8	124